Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma

Frontiers in Oncology

Oncology

Christoph Röcken¹  Sandra Krüger²  Steffen Heckl³  Tina Daunke⁴  Susanne Sebens⁴  Silje Beckinger⁴  Heiner Schäfer⁴  Leon Aldag⁴  Sascha Rahn⁵  Daniela Wesch⁶ 

[1] Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;Department of Pathology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;Department of Pathology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;Institute for Experimental Cancer Research, Kiel University and University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;Institute of Biochemistry, Kiel University, Kiel, Germany;Institute of Immunology, Kiel University and University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany;

关键词: pancreatic cancer;    immune evasion;    3D coculture;    hepatic metastasis;    programmed death ligand 1;    tumor microenvironment;   

DOI  :  10.3389/fonc.2023.1160824

 received in 2023-02-07, accepted in 2023-04-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionPancreatic ductal adenocarcinoma (PDAC) represents the 4th most common cause of cancer-related deaths in Western countries. Most patients are diagnosed at advanced stages, often already with metastases. The main site of metastasis is the liver and hepatic myofibroblasts (HMF) play a pivotal role in metastatic outgrowth. Immune checkpoint inhibitors (ICI) targeting programmed death ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) improved treatment of several cancers but not of PDAC. Therefore, this study aimed to better understand the impact of HMF on PD-L1 expression and immune evasion of PDAC cells during liver metastasis.MethodsFormalin-fixed and paraffin embedded biopsy samples or diagnostic resection specimens from liver metastases of 15 PDAC patients were used for immunohistochemical analyses. Serial sections were stained with antibodies directed against Pan-Cytokeratin, αSMA, CD8, and PD-L1. To investigate whether the PD-1/PD-L1 axis and HMF contribute to immune escape of PDAC liver metastases, a stroma enriched 3D spheroid coculture model was established in vitro, using two different PDAC cell lines, HMF, and CD8+ T cells. Here, functional and flow cytometry analyses were conducted.ResultsImmunohistochemical analysis of liver tissue sections of PDAC patients revealed that HMF represent an abundant stroma population in liver metastases, with clear differences in the spatial distribution in small (1500 µm) and large (> 1500 μm) metastases. In the latter, PD-L1 expression was mainly located at the invasion front or evenly distributed, while small metastases either lacked PD-L1 expression or showed mostly weak expression in the center. Double stainings revealed that PD-L1 is predominantly expressed by stromal cells, especially HMF. Small liver metastases with no or low PD-L1 expression comprised more CD8+ T cells in the tumor center, while large metastases exhibiting stronger PD-L1 expression comprised less CD8+ T cells being mostly located at the invasion front. HMF-enriched spheroid cocultures with different ratios of PDAC cells and HMF well mimicking conditions of hepatic metastases in situ. Here, HMF impaired the release of effector molecules by CD8+ T cells and the induction of PDAC cell death, an effect that was dependent on the amount of HMF but also of PDAC cells. ICI treatment led to elevated secretion of distinct CD8+ T cell effector molecules but did not increase PDAC cell death under either spheroid condition.ConclusionOur findings indicate a spatial reorganization of HMF, CD8+ T cells, and PD-L1 expression during progression of PDAC liver metastases. Furthermore, HMF potently impair the effector phenotype of CD8+ T cells but the PD-L1/PD-1 axis apparently plays a minor role in this scenario suggesting that immune evasion of PDAC liver metastases relies on other immunosuppressive mechanisms.

【 授权许可】

Unknown   
Copyright © 2023 Beckinger, Daunke, Aldag, Krüger, Heckl, Wesch, Schäfer, Röcken, Rahn and Sebens